Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTERNATION trial
2025-524312-11-00Phase 3Authorised
- Sponsor
- Medizinische Hochschule Hannover
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus in liver transplant (2 arms), sponsored by Medizinische Hochschule Hannover. Primary endpoint: Change in estimated glomerular filtration rate from baseline to month 14. Planned start Jun 2026; status: authorised.
02
Drugs
everolimus
03
Conditions
liver transplant
Beyond the preview
Go deeper on 2025-524312-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524312-11-00.